504 related articles for article (PubMed ID: 20085600)
21. In vitro analysis of birch-pollen-associated food allergy by use of recombinant allergens in the basophil activation test.
Erdmann SM; Sachs B; Schmidt A; Merk HF; Scheiner O; Moll-Slodowy S; Sauer I; Kwiecien R; Maderegger B; Hoffmann-Sommergruber K
Int Arch Allergy Immunol; 2005 Mar; 136(3):230-8. PubMed ID: 15713985
[TBL] [Abstract][Full Text] [Related]
22. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
Winther L; Malling HJ; Mosbech H
Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
[TBL] [Abstract][Full Text] [Related]
23. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
Buczyłko K; van der Werf JF; Boot D; van Ree R
Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study.
Horak F; Stübner P; Berger UE; Marks B; Toth J; Jäger S
J Investig Allergol Clin Immunol; 1998; 8(3):165-71. PubMed ID: 9684190
[TBL] [Abstract][Full Text] [Related]
25. Immunoglobulin G-dependent changes in basophil allergen threshold sensitivity during birch pollen immunotherapy.
Lalek N; Kosnik M; Silar M; Korosec P
Clin Exp Allergy; 2010 Aug; 40(8):1186-93. PubMed ID: 20528883
[TBL] [Abstract][Full Text] [Related]
26. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study.
Mauro M; Russello M; Incorvaia C; Gazzola GB; Di Cara G; Frati F
Eur Ann Allergy Clin Immunol; 2007 Apr; 39(4):119-22. PubMed ID: 17523385
[TBL] [Abstract][Full Text] [Related]
27. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
Pfaar O; Bachert C; Kuna P; Panzner P; Džupinová M; Klimek L; van Nimwegen MJ; Boot JD; Yu D; Opstelten DJE; de Kam PJ
J Allergy Clin Immunol; 2019 Mar; 143(3):970-977. PubMed ID: 30508538
[TBL] [Abstract][Full Text] [Related]
28. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE
J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.
Gadermaier E; Flicker S; Aberer W; Egger C; Reider N; Focke M; Vrtala S; Kundi M; Valenta R
Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093
[TBL] [Abstract][Full Text] [Related]
30. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
31. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
Hordijk GJ; Antvelink JB; Luwema RA
Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study.
Leynadier F; Banoun L; Dollois B; Terrier P; Epstein M; Guinnepain MT; Firon D; Traube C; Fadel R; André C
Clin Exp Allergy; 2001 Jul; 31(7):988-96. PubMed ID: 11467988
[TBL] [Abstract][Full Text] [Related]
33. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule.
Colás C; Monzón S; Venturini M; Lezaun A
J Allergy Clin Immunol; 2006 Apr; 117(4):810-6. PubMed ID: 16630938
[TBL] [Abstract][Full Text] [Related]
34. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
TePas EC; Hoyte EG; McIntire JJ; Umetsu DT
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
[TBL] [Abstract][Full Text] [Related]
35. Allergen immunotherapy for birch pollen-allergic patients: recent advances.
Moingeon P; Floch VB; Airouche S; Baron-Bodo V; Nony E; Mascarell L
Immunotherapy; 2016 May; 8(5):555-67. PubMed ID: 27140409
[TBL] [Abstract][Full Text] [Related]
36. BASALIT trial: double-blind placebo-controlled allergen immunotherapy with rBet v 1-FV in birch-related soya allergy.
Treudler R; Franke A; Schmiedeknecht A; Ballmer-Weber B; Worm M; Werfel T; Jappe U; Biedermann T; Schmitt J; Brehler R; Kleinheinz A; Kleine-Tebbe J; Brüning H; Ruëff F; Ring J; Saloga J; Schäkel K; Holzhauser T; Vieths S; Simon JC
Allergy; 2017 Aug; 72(8):1243-1253. PubMed ID: 27998002
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
Zieglmayer P; Focke-Tejkl M; Schmutz R; Lemell P; Zieglmayer R; Weber M; Kiss R; Blatt K; Valent P; Stolz F; Huber H; Neubauer A; Knoll A; Horak F; Henning R; Valenta R
EBioMedicine; 2016 Sep; 11():43-57. PubMed ID: 27650868
[TBL] [Abstract][Full Text] [Related]
38. A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study.
Pfaar O; van Twuijver E; Boot JD; Opstelten DJ; Klimek L; van Ree R; Diamant Z; Kuna P; Panzner P
Allergy; 2016 Jan; 71(1):99-107. PubMed ID: 26417901
[TBL] [Abstract][Full Text] [Related]
39. Phoenix sylvestris Roxb pollen allergy: a 2-year randomized controlled trial and follow-up study of immunotherapy in patients with seasonal allergy in an agricultural area of West Bengal, India.
Chakraborty P; Roy I; Chatterjee S; Chanda S; Gupta-Bharracharya S
J Investig Allergol Clin Immunol; 2006; 16(6):377-84. PubMed ID: 17153886
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
